ATLANTA, Feb. 20, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), brings to the attention of its shareholders a press release issued by Jay Pharma

MADRID, Feb. 20, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that four real-world data abstractsi,ii,iii,iv are being presented during the 13th Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid. The new data show that users of the FreeStyle Libre system have improved glucose co

PEARL RIVER, N.Y., Feb. 20, 2020 /PRNewswire/ -- Evolution Health Group (EHG), a full-service, global healthcare communications agency, is pleased to announce that Michael Stevinson has joined their team as Executive Vice President of their blulava division.

ATLANTA, Feb. 20, 2020 /PRNewswire/ -- Lawrence Thompson, Chief Strategy and Revenue Officer at Adv

CHICAGO, Feb. 20, 2020 /PRNewswire/ -- Hu-Friedy, the world leader in dental instrument manufacturing and instrument reprocessing workflows, today introduced HuFriedyGroup as the Dental Division of Cantel. This announcement follows an extensive and ongoing integration period that began in October when Cantel officially completed the acquisition of Hu-Friedy.

NESCONSET, N.Y., Feb. 20, 2020 /PRNewswire/ -- LifeVac, the revolutionary airway clearance device (ACD), has registered its fiftieth global save and fifth in 2020.  "We are pleased to add the fiftieth name to LifeVac' s Wall of Saves," said Arthur Lih, Founder and CEO of LifeVac. "More importantly, this is the first time in

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2019 financial results after market close on Thursday, February 27, 2020. Rigel senior management will follow the announcement with a live conference call and

SAN FRANCISCO, Feb. 20, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-foun

HOUSTON, Feb. 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has received an independent assessment of the absence of cardiotoxicity in patients treated with Annamycin in both i

LEBANON, N.J., Feb. 20, 2020 /PRNewswire/ -- Recordati Rare Diseases, Inc., a biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities in the U.S., today announced the transfer of U.S. marketing rights to SIGNIFOR® (pasireotide) injection and SIGNIFOR LAR® (pasireotide) for injectable sus